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ABSTRACT
Background The purpose of this study was to show 
whether and how levels, trends and patterns obtained 
from estimates of premature deaths from adverse effects 
(AEs) of medical treatment depended on the deprivation 
level in England over the 24-year period, 1990–2013. 
We provide a report to inform decision-making strategies 
to reduce the burden of disease arising from AEs of 
medical treatment in the most deprived areas of the 
country.
Methods Comparative analysis was driven by a single 
cause-of-injury category—AEs of medical treatment—
from the Global Burden of Disease 2013 study. We 
report the mean values with 95% uncertainty intervals 
(UIs) for five socioeconomic deprivation areas of England.
Results In the most deprived areas of England, the 
death rate declined from 2.27 (95% UI 1.65 to 2.57) 
to 1.54 (1.28 to 2.08) deaths (32.16% change). The 
death rate in the least deprived areas was 1.22 (0.88 
to 1.38) in 1990; it was 1.17 (0.97 to 1.59) in 2013 
(4.1% change). Regarding disability-adjusted life year 
(DALY) rates, the same trend is observed. Although the 
gap between the most deprived and least deprived 
populations of England narrowed with regards to 
number of deaths, and rates of deaths and DALYs from 
AEs of medical treatment, inequalities between marginal 
levels of deprivation remain.
Conclusions The study suggests that a relationship 
between deprivation level and health loss from the AEs 
of medical treatment across England is possible. This 
could then be used when devising and prioritising health 
policies and strategies.
InTRoduCTIon
Effects of socioeconomic deprivation on overall 
health status, life expectancy, incidence, preva-
lence and mortality from a range of diseases and 
surgeries are well understood.1–4 However, there is 
little information on how various levels of socio-
economic deprivation impact on health loss arising 
from adverse effects (AEs) of medical treatment.
It has recently been reported that, in England, 
marked health inequalities between the least 
deprived and most deprived English populations 
remain despite the fact that mortality and disabili-
ty-adjusted life year (DALY) rates from 306 diseases 
and injuries have decreased in the country over the 
period 1990–2013.5 6 Insight into the relationship 
between deprivation level and premature mortality 
from a single cause-of-injury category—AEs of 
medical treatment—in the country is important 
because clinical AEs are gaining more public and 
media attention. AEs are often related to human 
error and the opportunity, therefore, to reduce 
the disease burden from preventable AEs should 
be explored.7 8 Furthermore, routine mortality 
statistics undifferentiated by deprivation level can 
mask inequalities between subpopulations of the 
country.5
Previous reports on clinical outcomes from AEs 
of medical treatment in England were based on 
either the annual number of patient safety-related 
incidents—less than 0.5% of incidents involved 
death4—or a review of randomly drawn medical 
records at acute-care hospitals in one region of 
England—8% case fatality rate reported.9 A wider 
range of case fatality rates from AEs of medical 
treatment was reported in other high-income 
low-mortality countries—1.5%–21%.10 11 A rela-
tionship between socioeconomic deprivation level 
and mortality from the AEs of medical treatment in 
England has not been reported.
The purpose of this study was to show whether 
and, if so, how levels, trends and patterns obtained 
from estimates of premature deaths from AEs of 
medical treatment depended on deprivation level 
in England over the 24-year period, 1990–2013. 
We aimed to provide a pertinent report to poli-
cy-makers and healthcare professionals that could 
be used for planning strategies to reduce the burden 
of disease arising from AEs of medical treatment 
in the most deprived areas of England. We used 
a single cause-of-injury category—AEs of medical 
treatment—from the Global Burden of Disease 
(GBD) 2013 study for this analysis.
MeThodS
GBd study
The GBD 2013 is a systematic, comprehensive 
effort to quantify health loss from 306 causes of 
diseases, 240 causes of death and 79 risk factors by 
gender and age groups between 1990 and 2013 for 
188 countries. Detailed descriptions of the method-
ology of the GBD 2013 study, including the estima-
tion process used in generating mortality and DALYs 
for every single cause, are provided elsewhere.12–14
Study country
The scheme of nine English regions is shown in 
figure 1. They all correspond to the European 
boundaries of the Nomenclature for Territorial 
Statistics level 1 regions. The methodology of a divi-
sion of the territory of England into small relatively 
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homogeneous geographic areas termed as lower super output 
areas, covering about 1600 people in average, its further ranking 
and grouping into 45 subregional deprivation areas and five 
summary deprivation levels were described elsewhere.5 Briefly, 
each of the nine English regions was divided into five areas by 
equal fifth (ie, quintile) of population deprivation based on the 
Index of Multiple Deprivation 2010, which is a composite index 
resulting from seven domains, weighted as follows: income 
(22.5%), employment (22.5%), health and disability (13.5%), 
education, skills and training (13.5%), barriers to housing and 
services (9.3%), living environment (9.3%) and crime (9.3%). 
For a factor of regional geography accounts for only a small 
proportion of the variance between deprivation areas in England, 
all 45 deprivation areas of the nine regions of England were 
grouped into five levels.15 The most deprived areas are referred 
to as deprivation level 1, moderately deprived areas as depriva-
tion level 3 and the least deprived areas as deprivation level 5.5
The National Health Service (NHS) England is a key provider 
of comprehensive healthcare service for the whole population 
of this country. The principle of equity—provision of the same 
healthcare to all residents of the country regardless of ability 
to pay, age, gender, race, ethnicity and social factors—is the 
NHS core. The organised provision of unplanned and planned 
medical care in the NHS to an individual is free of charge (with a 
few exceptions permitted by Parliament) at the point of delivery 
of care. Despite numerous political and organisational changes 
since the foundation of NHS in 1948, it remains to date a service 
available universally that cares for people of England, Scotland, 
Wales and Northern Ireland by need. To note, the NHS is funded 
by taxes and national insurance contributions. The Department 
of Health (https://www. gov. uk/ government) is the responsible 
body for the direction of the NHS England by developing poli-
cies and strategies, securing resources, setting national standards 
and monitoring performance. Further introductory informa-
tion regarding the healthcare system in England and the UK are 
provided elsewhere.16 17
Aes of medical treatment
Coded AEs from both hospitals and emergency departments 
were included into the process of methodological estimations for 
GBD 2013 study. The International Classification of Diseases, 
Ninth Revision (ICD-9) and The International Statistical Clas-
sification of Diseases and Related Health Problems, Tenth Revi-
sion (ICD-10) were used to code AEs of medical treatment. A 
detailed list of 311 codes and other supplemental information on 
the burden of injury from AEs of medical treatment are available 
in the annex of Global Burden of Injury paper.14
estimates
The loss of health from AEs of medical treatment was measured 
in number of deaths and rates of deaths and DALYs. An online, 
interactive, data visualisation tool (http:// vizhub. healthdata. org/ 
gbd- compare/ england), launched on 14 September 2015, was 
used to retrieve the estimates for mortality and DALYs from AEs 
of medical treatment for England and the nine English regions 
Figure 1 Scheme of nine English regions.
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at every deprivation level and overall.6 We extracted the means 
with 95% uncertainty intervals (UIs) for number of deaths, and 
death and DALY rates per 100 000 men and women of all ages at 
the year 1990, 1995, 2000, 2005, 2010 and 2013.
Mortality and dALY estimation
Although mortality data in England is assumed to be complete 
as it is a legal necessity to register every death, it is not accu-
rate.5 For this reason, the cause of death ensemble modelling 
(CODEm) software was used to derive most probable estimates 
with 95% UIs for mortality from AEs arising from medical treat-
ment. It minimises the effect of highly possible stochastic varia-
tion between regions. Multiplication of number of deaths by the 
residual expected individual life span at the age of death from 
the GBD 2013 standard model life table provided the years of 
life lost (YLLs) due to premature death. Disability secondary to 
AEs of medical treatment was estimated as a product multiplica-
tion of prevalence of individuals in each sequela and the appro-
priate disability weight for the corresponding health state.13 It is 
important to note that it was not possible to estimate the proba-
bility of permanent health loss from AEs of medical treatment in 
England due to inadequate data. To produce final estimates for 
years lived with disability (YLDs), the Bayesian meta-regression 
method DisMod-MR 2.0 was used. The sum of YLL and YLD is 
a DALY.
UIs express measurement error affecting all data inputs. They 
are presented by the 2.5 and 97.5 centile values. The 95% UI 
estimation for the mean value is inherited within the GBD 
methods. It is propagated using 1000 draws from the posterior 
distribution in the estimation process of the metrics. We calcu-
lated the percentage difference between the means for depriva-
tion levels 1 and 5 at the same time points, and the percentage 
change between two values at different points in time.
ethics
Ethical approval from research ethics committees or institutional 
review boards is not required for this analytical study.
ReSuLTS
deaths
In England, in 1990, an estimated 890.7 (95% UI 644.41 to 
999.76) and, in 2013, 776.39 (95% UI 645.07 to 1045.15) 
inhabitants died from AEs of medical treatment. Figure 2 shows 
a distinct pattern of disproportional distributions of deaths from 
AEs of medical treatment remains in England—deaths were 
more frequent in most deprived areas of the country. The sum 
of percentage proportions from two most deprived levels, 1 and 
2, was 48.26% in 1990 and 43.11% in 2013. Only 12.57% of 
deaths were attributed to level 5 in 1990 and 15.83% in 2013. In 
contrast, a proportion of deaths attributed to deprivation level 1 
made up 25.59% (of 891 deaths) in 1990 and 21.62% (of 777 
deaths) in 2013.
death rates
Death rates from AEs of medical treatment in England are 
presented in table 1. Between 1990 and 2013, the AE death rate 
dropped by 32.16% at deprivation level 1, that is, from 2.27 to 
1.54 deaths per 100 000 individuals, whereas the AE death rate 
declined by 4.1% at deprivation level 5 in England—from 1.22 
to 1.17 deaths—from 1990 to 2013.
Regarding the death rates in the English regions, they were 
higher in all most deprived (level 1) areas of England in compar-
ison with least deprived (level 5) areas in both 1990 and 2013, 
except for Greater London in the year 2013 where the death 
rate was higher by 11.65% in the least deprived areas. It is note-
worthy that three regions of England—North East, East and 
South East—had most prominent disparities in AE death rates 
between level 1 and level 5 in 1990 and 2013. For instance, the 
North East of England is a particular region in this respect as 
disparities between death rates at level 1 and level 5 were excep-
tionally high in 1990 (114.53%) and high in 2013 (44.14%).
Figure 3 shows trends in England from the mean rates of 
deaths per 100 000 individuals of both genders combined, by 
deprivation level, from 1990 to 2013. Lowest death rates from 
AEs at level 5 (least deprived population) remained stable over 
a period of 24 years. AE death rates for deprivation levels 1, 
Figure 2 A pattern of disproportional distribution of deaths from adverse effects of medical treatment in a 100% stacked column chart for five 
levels of deprivation in England between 1990 and 2013. The numbers of deaths (as means) are displayed in 30 colour-coded fractions of the columns. 
Level 1, most deprived; level 3, moderately deprived; level 5, least deprived.
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2 and 3 declined; the trend lines converged in 2010–2013. 
The percentage difference between the AE death rates for least 
deprived (level 5) and most deprived (level 1) populations of 
England was substantial in 2013—27.31%.
dALY rates
Figure 4 reveals inequalities in DALY rates per 100 000 men and 
women in England, by deprivation level and year. Highest DALY 
rates are found among the most deprived (33.72 per 100 000 
men and 31.98 DALY rate per 100 000 women in 2013) and 
lowest DALY rates (22 DALY per 100 000 men and 22.74 per 
100 000 women in 2013) are found among the least deprived. 
Importantly, the trend line for the moderately deprived (level 
3) is strictly between marginal levels, and there are no cross-
overs in trend lines 1, 3 and 5 for men and women. Further-
more, figure 4 shows that variations in DALY rates across the 
least deprived (levels 4 and 5) areas were minimal in England 
between 1990 and 2013. Besides, this figure shows that DALY 
rates decreased by 47.41% in women and 27.75% in men at 
deprivation level 1, and by 33.08% in women and by 27.17% 
in men at deprivation level 2 from 1990 to 2013. Although the 
disparities in AE DALY rates between the most deprived and 
least deprived areas decreased in England over time, inequalities 
between them remain.
Figure 5 shows the difference between DALY rates for depri-
vation levels 1 and 5 in 2013, by gender and regional geography 
of England. The blue colour-coded percentage proportions for 
DALY rates for most deprived areas (level 1) are more apparent 
than red colour-coded proportions for least deprived areas (level 
5). It indicates that DALY rates in most deprived populations 
are higher than in the least deprived ones in the country. This 
pattern is not pertinent only for women from Greater London.
DALY rates with 95% UIs per 100 000 individuals of both 
genders combined from marginal deprivation levels in England 
and the English regions in 1990 and 2013 are provided in 
table 2. In 2013, they were lower in all regions of England but 
West Midlands where DALY rate was higher by 3.02% in the 
least deprived (level 5) areas. It is important to note that the 
largest share of DALY originated from YLL—78.38% (95% UI 
75.6 to 81.56) and 78.1% (95% UI 77.28 to 82.54) for men 
and women in England in 2013, respectively. The remainder is 
attributable to YLD.
dISCuSSIon
Results of this analysis suggest an analogical relationship between 
the level of deprivation and the rates of deaths and DALYs from 
AEs of medical treatment in England. We hypothesise that the 
burden of AEs of medical treatment is heavier in most deprived 
populations because the overall health status is more fragile in 
those patients. This leads to decreased life expectancy and an 
increase in mortality from a wide range of primary medical condi-
tions.1 2 Interestingly, previous studies have shown that patients 
in the most deprived populations are subject to more generic 
prescribing, drug selection, more frequent antibiotic prescribing 
and a trend to polypharmacy.18–21 The greater use of cardiovas-
cular drugs in the most deprived young patients with a softer 
diagnosis of angina pectoris is one example of polypharmacy.21 
These phenomena are associated with increased occurrence of 
AEs of medical treatment, and perioperative AE rates are shown 
to be higher in patients from most deprived populations.3
Findings of our study highlight that deprivation level affects 
the outcomes of AEs of medical treatment in England. This 
suggests that further focused efforts to reduce disparities across 
different socioeconomic groups are needed to narrow the gap 
or achieve equity in outcomes from AEs across the country. 
Shulman et al show increased AEs in patients of low socioeco-
nomic status using insulin pumps and propose specific guidelines 
to manage this.22
Results of this study demonstrate, too, that the differences in 
death and DALY rates from AEs of medical treatment between 
the most deprived and least deprived populations decreased over 
our study period. This is mainly due to a marked decrease in 
death and DALY rates from AEs in most deprived populations. 
Table 1 Death rates with 95% uncertainty intervals for adverse effects of medical treatment per 100 000 all-age individuals of both genders 
combined in England and the English regions in 1990 and 2013, by level 1 (most deprived) and level 5 (least deprived)
1990 Percentage 
difference
2013 Percentage 
differenceLevel 1 Level 5 Level 1 Level 5
England 2.27 (1.65 to 2.57) 1.22 (0.88 to 1.38) 60.17 1.54 (1.28 to 2.08) 1.17 (0.97 to 1.59) 27.31
East of England 1.99 (1.32 to 2.39) 1.16 (0.8 to 1.4) 52.7 2.08 (1.56 to 3.16) 0.95 (0.73 to 1.38) 74.59
East Midlands 2.23 (1.54 to 2.77) 1.16 (0.79 to 1.46) 63.13 1.97 (1.49 to 2.89) 1.28 (0.96 to 1.89) 42.46
Greater London 2.11 (1.52 to 2.49) 1.37 (0.93 to 1.63) 42.53 0.97 (0.74 to 1.39) 1.09 (0.81 to 1.65) 11.65
North East of England 2.76 (1.98 to 3.36) 0.75 (0.53 to 0.95) 114.53 1.77 (1.33 to 2.53) 1.13 (0.86 to 1.61) 44.14
North West of England 2.23 (1.49 to 2.65) 1.67 (1.08 to 2.08) 28.72 1.61 (1.23 to 2.3) 1.53 (1.15 to 2.14) 5.1
South East of England 2.37 (1.63 to 2.83) 1.02 (0.69 to 1.22) 79.65 1.64 (1.23 to 2.28) 1 (0.75 to 1.39) 48.48
South West of England 1.37 (1 to 1.61) 1.29 (0.87 to 1.55) 6.02 1.45 (1.11 to 1.99) 1.17 (0.89 to 1.62) 21.37
West Midlands 2.41 (1.73 to 2.95) 1.18 (0.85 to 1.51) 68.52 1.88 (1.4 to 2.5) 1.64 (1.22 to 2.28) 13.64
Yorkshire and the Humber 2.4 (1.64 to 2.84) 1.61 (1.05 to 1.98) 39.4 1.39 (1.1 to 2.06) 1.32 (1.04 to 2) 5.17
Estimates for years 1990, 1995, 2000, 2005, 2010 and 2013 are available at http://vizhub.healthdata.org/gbd-compare/england.
Figure 3 Trends for all-age death rates per 100 000 individuals of 
both genders in England by deprivation level from 1990 to 2013. Level 
1, most deprived; level 3, moderately deprived; level 5, least deprived.
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There are several plausible explanations for this: First, bearing 
in mind that life expectancy at birth increased by 5.4 years in 
England, from 75.9 years to 81.3 years, and age-standardised 
death rate was reduced by 33.6% between 1990 and 2013,5 we 
assume that the reduction of those gaps between most deprived 
and least deprived populations was driven by an overall health 
status improvement in men and women from the most deprived 
populations. Second, we hypothesise that long-term programmes 
and interventions aimed to manage clinical risk and increase 
patient safety (https://www. england. nhs. uk/ patientsafety/) had 
more impact on deprived patients than their affluent counter-
parts. Finally, the policy that the NHS is delivering universal and 
equitable modern secondary prevention and treatment measures 
for common health conditions independently of socioeconomic 
circumstances of patients contributed positively in reduction of 
health loss from hospital AEs following complex therapies.21
Regarding the interpretation of results for Greater London, 
it was postulated that the overall burden of disease is less than 
expected in the most deprived groups because of a possible error 
in the deprivation measuring method, the ethnic composition of 
the population, healthy migrant effect and selective differential 
migration.5 However, other studies have suggested that there 
are poorer outcomes overall on physical and mental health for 
non-UK-born individuals residing in the UK compared with the 
UK population.23 Some degree of uncertainty thus remains.
Our analysis has limitations. We could not provide informa-
tion on incidence and prevalence of AEs of medical treatment 
by deprivation level in England. This could be demonstrated by 
Figure 4 Inequalities in trends for disability-adjusted life year (DALY) rates per 100 000 men and women of all ages in England by deprivation level 
from 1990 to 2013; left-side chart for women, right-side chart for men. Level 1, most deprived; level 3, moderately deprived; level 5, least deprived.
Figure 5 Percentage proportions in 100% stacked bar chart from the mean disability-adjusted life year (DALY) rates for level 1 (most deprived) and 
level 5 (least deprived) areas across nine regions of England and England per 100 000 women and men of all ages in 2013. Domination of blue colour 
bars over red colour bars shows that DALY-related burden of adverse effects of medical treatment in most deprived areas of England is distinct from 
least deprived ones.
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further analyses based on GBD studies. Bias associated with a 
definition of AEs of medical treatment and selection of ICD-9 
and ICD-10 codes is possible. A more detailed analysis based 
on an individual AE code or cluster of codes would identify 
the proportions of AEs specifically related to pharmacological, 
surgical and radiological treatments within different socioeco-
nomic groups. It would also be important to depict the impact 
of deprivation level on the AEs of medical treatment in Northern 
Ireland, Scotland and Wales.
This analysis also provides some valuable insights into 
the distribution of AEs of medical treatment in England, by 
region, gender and deprivation level between 1990 and 2013. 
It transpires that the highest rates of deaths and DALYs were 
observed in both Northern regions and Greater London in 
1990; in East of England and both Northern regions of England 
in 2013. Furthermore, inequalities in adverse outcomes from 
AEs arising from medical care remain, although the NHS in 
England is delivering equitable treatment to all residents of 
the country independently of deprivation level. This indi-
cates that other determinants of health status may influence 
outcomes of medical therapies and play a role in the occur-
rence of AEs. Examples may include the socioeconomic class-
based differences within ethnic groups, racial differences in 
the society, duration of cultural adaptation of newly arrived 
residents and effects of preventative medicine interventions 
for groups of residents at higher risk of illness.24–26 Overall, 
our study supplements a systematic analysis of changes in 
health in England, for it precisely pinpoints the levels, shows 
the trends and highlights the patterns of health loss from AEs 
of medical treatment in the population of this country over 
the 24-year period.5 It provides a platform for further research 
based on specific ICD-10 codes to clarify the burden of indi-
vidual AEs of medical treatment in England. This could help 
to understand causes and circumstances associated with them, 
and develop AE prevention strategies.27
In conclusion, our study suggests that a relationship between 
deprivation level and health loss from the AEs of medical treat-
ment across England and its regions is possible. This could then 
inform those responsible for devising and prioritising health 
policies and strategies.
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Table 2 All-age disability-adjusted life year rates with 95% uncertainty intervals for adverse effects of medical treatment per 100 000 individuals 
of both genders combined in England and the English regions in 1990 and 2013 by deprivation levels 1 and 5
1990 Percentage 
difference
2013 Percentage 
differenceLevel 1 Level 5 Level 1 Level 5
England 53.27 (41.99 to 60.93) 23.97 (18.72 to 27.25) 75.87 32.34 (26.4 to 41.62) 22.37 (18.47 to 28.85) 36.45
East of England 43.68 (33.16 to 51.25) 24.8 (18.97 to 28.95) 55.14 41.82 (33.62 to 54.27) 19.83 (15.89 to 26.1) 71.34
East Midlands 52.56 (40.5 to 61.75) 24.65 (19.43 to 29.13) 72.3 31.44 (30.41 to 49.42) 22.23 (18.12 to 29.42) 34.32
Greater London 51.44 (40.13 to 60.08) 28.48 (21.49 to 32.97) 57.46 24.65 (19.31 to 33.24) 22.78 (18.06 to 31.05) 7.89
North East of England 59.23 (45.05 to 70.29) 14.34 (11.07 to 17.09) 122.03 34.06 (26.87 to 45.25) 25.24 (19.8 to 33.15) 29.75
North West of England 51.48 (39.32 to 59.59) 27.84 (20.43 to 32.83) 59.61 33.47 (27.29 to 43.79) 25.79 (20.97 to 32.73) 25.92
South East of England 53.51 (41.11 to 63.19) 20.68 (15.76 to 24.16) 88.5 32.57 (25.78 to 42.99) 19.22 (15.2 to 25.3) 51.55
South West of England 37.86 (29.92 to 44.78) 24.38 (18.59 to 28.71) 43.32 30.3 (24.31 to 38.31) 21.99 (17.75 to 28.02) 31.78
West Midlands 37.86 (29.92 to 44.78) 24.18 (18.82 to 29.49) 44.1 30.3 (24.31 to 38.31) 31.23 (24.88 to 40.65) 3.02
Yorkshire and the Humber 57.32 (44.35 to 66.83) 28.04 (21.15 to 33.1) 68.6 30.22 (24.51 to 39.84) 25.72 (20.78 to 34.72) 16.09
Details for years 1990, 1995, 2000, 2005, 2010 and 2013 are available at http://vizhub.healthdata.org/gbd-compare/england.
What is already known on the subject
 ► Important previous reports on outcomes from adverse effects 
(AEs) of medical treatment in England were based on  either 
the annual number of patient safety-related incidents or a 
review of randomly drawn medical records at acute-care 
hospitals in one region of England.
What this study adds
 ► We present levels, trends and patterns from deaths and 
disability-adjusted life years (DALYs) with relation to 
socioeconomic deprivation for England (and the nine English 
regions) over the period 1990–2013.
 ► We demonstrate that the gap between the most deprived 
and least deprived populations narrowed with regards to 
number of deaths and the rates of deaths and DALYs.
 ► We highlight that inequality remains between marginal 
deprivation levels across England and within its regions 
in terms of death and DALY rates from AEs of medical 
treatment.
 ► We state that a relationship between deprivation level and 
health loss from the AEs of medical treatment is possible.
 ► We provide a report to inform decision-making strategies 
to reduce the burden of disease arising from AEs of medical 
treatment in the most deprived areas of England.
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